VITRAKVI Drug Patent Profile

Which patents cover Vitrakvi, and when can generic versions of Vitrakvi launch?

Vitrakvi is a drug marketed by Bayer Hlthcare and Bayer Healthcare and is included in two NDAs. There are twenty patents protecting this drug and one Paragraph IV challenge.

This drug has two hundred and ninety-one patent family members in fifty countries.

The generic ingredient in VITRAKVI is larotrectinib sulfate. Two suppliers are listed for this compound. Additional details are available on the larotrectinib sulfate profile page.

DrugPatentWatch^® Generic Entry Outlook for Vitrakvi

Vitrakvi was eligible for patent challenges on November 26, 2022.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be August 15, 2036. This may change due to patent challenges or generic licensing.

There have been nine patent litigation cases involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.

Indicators of Generic Entry

Summary for VITRAKVI

International Patents:	291
US Patents:	20
Applicants:	2
NDAs:	2
Finished Product Suppliers / Packagers:	2
Raw Ingredient (Bulk) Api Vendors:	121
Clinical Trials:	5
Patent Applications:	1,174
Drug Prices:	Drug price information for VITRAKVI
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for VITRAKVI
What excipients (inactive ingredients) are in VITRAKVI?	VITRAKVI excipients list
DailyMed Link:	VITRAKVI at DailyMed

See drug prices for VITRAKVI

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for VITRAKVI

NDA:

210861

Dosage:

CAPSULE;ORAL

NDA:

211710

Dosage:

SOLUTION;ORAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for VITRAKVI

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
M.D. Anderson Cancer Center	Phase 2
Children's Oncology Group	Phase 2
Eli Lilly and Company	Phase 2

See all VITRAKVI clinical trials

Pharmacology for VITRAKVI

Drug Class	Kinase Inhibitor
Mechanism of Action	Tropomyosin Receptor Kinases Inhibitors

Paragraph IV (Patent) Challenges for VITRAKVI

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
VITRAKVI	Capsules	larotrectinib sulfate	25 mg and 100 mg	210861	1	2025-05-06

US Patents and Regulatory Information for VITRAKVI

VITRAKVI is protected by twenty-one US patents.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Bayer Healthcare	VITRAKVI	larotrectinib sulfate	SOLUTION;ORAL	211710-001	Nov 26, 2018		RX	Yes	Yes
Bayer Healthcare	VITRAKVI	larotrectinib sulfate	SOLUTION;ORAL	211710-001	Nov 26, 2018		RX	Yes	Yes
Bayer Healthcare	VITRAKVI	larotrectinib sulfate	SOLUTION;ORAL	211710-001	Nov 26, 2018		RX	Yes	Yes			Y
Bayer Hlthcare	VITRAKVI	larotrectinib sulfate	CAPSULE;ORAL	210861-002	Nov 26, 2018		RX	Yes	Yes			Y	Y
Bayer Healthcare	VITRAKVI	larotrectinib sulfate	SOLUTION;ORAL	211710-001	Nov 26, 2018		RX	Yes	Yes
Bayer Hlthcare	VITRAKVI	larotrectinib sulfate	CAPSULE;ORAL	210861-002	Nov 26, 2018		RX	Yes	Yes			Y	Y

International Patents for VITRAKVI

When does loss-of-exclusivity occur for VITRAKVI?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Argentina

Australia

Brazil

Canada

Chile

China

Colombia

Costa Rica

Croatia

Cuba

Cyprus

Denmark

Dominican Republic

Ecuador

European Patent Office

Finland

Georgia, Republic of

Hong Kong

Hungary

Israel

Japan

Lithuania

Mexico

Morocco

New Zealand

Nicaragua

Peru

Philippines

Poland

Portugal

Russian Federation

Saudi Arabia

Serbia

Singapore

Slovenia

South Africa

South Korea

Spain

Taiwan

Tunisia

Ukraine

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering VITRAKVI around the world.

Country	Patent Number	Title	Estimated Expiration
Argentina	074052	COMPUESTOS PIRAZOLO{1,5-A}PIRIMIDINA SUSTITUIDA COMO INHIBIDORES DE TRK CINASA
Argentina	112833	COMPUESTOS PIRAZOLO[1,5-A]PIRIMIDINA SUSTITUIDA COMO INHIBIDORES DE TRK CINASA
Australia	2009308465	Substituted pyrazolo[1,5-a]pyrimidine compounds as TRK kinase inhibitors
Australia	2015200511	SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINE COMPOUNDS AS TRK KINASE INHIBITORS
Australia	2017268517	SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINE COMPOUNDS AS TRK KINASE INHIBITORS
Australia	2019275599

Supplementary Protection Certificates for VITRAKVI

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
3106463	301033	Netherlands		PRODUCT NAME: LAROTRECTINIB, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT, IN HET BIJZONDER LAROTRECTINIBSULFAAT, MET INBEGRIP VAN LAROTRECTINIBSULFAAT MONOHYDRAAT; REGISTRATION NO/DATE: EU/1/19/1385 20190923
3106463	PA2020504	Lithuania		PRODUCT NAME: LAROTREKTINIBAS IR (ARBA) FARMACINIU POZIURIU PRIIMTINOS DRUSKOS, YPAC LAROTREKTINIBO SULFATAS, ISKAITANT LAROTREKTINIBO VANDENILIO SULFATA; REGISTRATION NO/DATE: EU/1/19/1385 20190919
3106463	CA 2020 00013	Denmark		PRODUCT NAME: LAROTRECTINIB OG/ELLER ET FARMACEUTISK ACCEPTABELT SALT DERAF, SAERLIGT LAROTRECTINIBSULFAT, INKLUSIV LAROTRECTINIBHYDROGENSULFAT; REG. NO/DATE: EU/1/19/1385 20190923
3106463	122020000012	Germany		PRODUCT NAME: LAROTRECTINIB ODER ANDERE PHARMAZEUTISCH ANNEHMBARE SALZE DAVON, EINSCHLIESSLICH LAROTRECTINIBSULFATE UMFASSEND LAROTRECTINIBHYDROGENSULFAT; REGISTRATION NO/DATE: EU/1/19/1385 20190919
3106463	LUC00150	Luxembourg		PRODUCT NAME: LAROTRECTINIB ET/OU SES SELS PHARMACEUTIQUEMENT ACCEPTABLES, EN PARTICULIER LE SULFATE DE LAROTRECTINIB, Y COMPRIS L'HYDROGENOSULFATE DE LAROTRECTINIB; AUTHORISATION NUMBER AND DATE: EU/1/19/1385 20190923
3106463	2020C/507	Belgium		PRODUCT NAME: VITRAKVI - LAROTRECTINIB ET/OU SES SELS ACCEPTABLES EN PHARMACIE, EN PARTICULIER L'HYDROGENO SULFATE DE LAROTRECTINIB; AUTHORISATION NUMBER AND DATE: EU/1/19/1385 20190923

VITRAKVI (larotrectinib) market dynamics and financial trajectory: sales trend, exclusivity, competition, and patent-driven risk

Last updated: July 21, 2026

VITRAKVI (larotrectinib; Loxo/indicated as TRK inhibitor) is a niche but growing oncology franchise driven by broad biomarker selection (NTRK gene fusions) across tumor types. The revenue trajectory has been defined by (1) label expansion via pediatric and adult solid-tumor studies, (2) commercial adoption for NTRK fusion testing, and (3) competitive pressure from next-generation TRK inhibitors and broader targeted oncology standard-of-care shifts. Patent protection materially limits generic entry and has supported premium pricing, with exclusivity and Orange Book-style barriers acting as the main near-to-midterm shield against unbranded competition in the US.

---

How is VITRAKVI performing commercially (sales trend, growth drivers, and what’s driving demand)?

Answer (snapshot): VITRAKVI is characterized by a payer-facing premium in a small patient population where demand is primarily constrained by access to NTRK fusion testing and oncologist awareness rather than by label saturation. Revenue growth tracks new prespecified label cohorts and expanding guideline use for NTRK fusion–positive solid tumors, including pediatric indications.

Sales dynamics that typically move VITRAKVI

• Biomarker identification rate: Uptake tracks the rate at which health systems order NTRK fusion testing (often multiplex RNA/DNA panels) and convert positive results into targeted prescribing.
• Line-of-therapy migration: Clinician preference moves from later-line refractory use toward earlier targeted adoption where trial evidence and guideline positioning support it.
• Regional reimbursement: Access improves in geographies with favorable coverage for biomarker-driven oncology and where specialty pharmacy distribution reduces friction.
• Treatment duration: For responders, continuing therapy drives durable revenue per patient; interruptions reduce lifetime value.

Key market variables to monitor

• Testing volume growth (biomarker panel adoption, turnaround times, reimbursement for testing).
• Reflex testing policies at large oncology centers.
• Payer utilization management (prior authorization criteria tied to NTRK fusion positivity and prior therapy history, where applicable).
• Site-of-care mix (hospital oncology vs outpatient specialty infusion workflows, though larotrectinib is oral).

---

When does VITRAKVI lose exclusivity and how does that affect revenue planning?

Answer (snapshot): VITRAKVI’s revenue risk is primarily tied to US patent expiration and any pediatric exclusivity extensions associated with its qualifying approvals, with generic and branded-competition scenarios dependent on Paragraph IV timing and successful infringement defenses.

What revenue planners model around exclusivity

• US patent expiry schedule: Each independent patent family’s final expiration sets the theoretical ceiling for generic launch timing.
• Market exclusivity vs patent exclusivity: Regulatory exclusivity blocks certain approvals; patents block marketing. A product can face patent expiry even if regulatory exclusivity remains, or vice versa.
• Pediatric exclusivity overlays: If triggered, pediatric exclusivity can extend market exclusivity for eligible indications, shifting generic timing in some cases.

How exclusivity affects pricing power

• During the period where patents and exclusivity are intact, VITRAKVI pricing typically stays closer to launch positioning, supported by limited therapeutic alternatives for NTRK fusion contexts.
• After expiry, pricing pressure usually begins before the first generic sale through payer contracting leverage and switching pressure.

---

What patent estate and Orange Book barriers matter for VITRAKVI generic competition?

Answer (snapshot): The controlling barrier is the patent estate listed in the US for larotrectinib, covering drug substance, formulations, and potentially method-of-use and use in specific indications. These listings typically define whether a generic can file an abbreviated pathway and how likely it is to succeed in Paragraph IV litigation.

Patent estate elements that shape generic risk

• Drug substance patents: Highest-likelihood blockers for unbranded entry.
• Formulation and manufacturing patents: Can block “drop-in” generic approaches even when composition patents fall.
• Method-of-use patents: Affect label-specific generic entry and forced market reversion to narrower or off-label usage.

Where revenue can be exposed even before first generic launch

• “Authorized generic” or settlement-driven earlier entry: Settlement terms can accelerate effective competition.
• Label carve-outs: If the generics enter on a narrow label, sales may fragment by indication rather than face an across-the-board pricing shock.

---

How strong is the competitive landscape for NTRK fusion therapies versus VITRAKVI?

Answer (snapshot): VITRAKVI competes within the TRK inhibitor class where efficacy and tolerability, including CNS penetration profiles and adverse-event management, determine switching. In practice, clinicians and payers often choose based on trial data maturity, access, patient-specific toxicity and comorbidity profiles, and convenience.

Competitive dimensions that determine share

• Adverse event management: Dose modifications and discontinuation rates shape real-world persistence.
• Line-of-therapy position: If a competitor claims or demonstrates a stronger fit for earlier lines, share can migrate.
• Patient coverage by biomarker: Broader fusion partner coverage or faster response can expand addressable use cases.

Comparison approach that matters for revenue

• First-line targeted adoption vs refractory-only: Earlier adoption increases addressable patients.
• Pediatric uptake: Pediatric use has a disproportionate impact on lifetime value because treatment duration can be longer.

---

What generic entry risks exist for VITRAKVI under Paragraph IV and settlements?

Answer (snapshot): Generic entry risk is tied to (1) Paragraph IV filings against Orange Book-listed patents and (2) settlement or litigation outcomes that control launch dates. The revenue implication is usually discontinuous: either delayed, or sudden pricing contraction after effective launch.

How Paragraph IV risk translates to financials

• Probabilistic launch modeling: Analysts typically model an FDA approval timeline combined with a launch date that depends on litigation stay and court outcomes.
• Settlement-driven entry windows: If a settlement occurs, the launch date may shift earlier than the final merits outcome would imply, reducing the remaining sales plateau.

What to watch for in filings and docket updates

• Paragraph IV patent subset: The particular patents challenged can indicate whether the challenger is attacking drug substance or formulation and therefore how vulnerable the product is.
• Requested carve-outs: If a challenger seeks to enter with narrow indication coverage, commercial impact depends on how VITRAKVI revenue is distributed by indication.

---

How does FDA regulatory status for VITRAKVI affect market access and sales durability?

Answer (snapshot): FDA label breadth, including tumor-agnostic approvals and pediatric inclusion where applicable, enables use across a large set of NTRK fusion–positive tumors, sustaining durable demand as testing becomes routine.

Regulatory factors with direct commercial impact

• Tumor-agnostic positioning: Broad label reduces “indication-specific” payer denials and improves switching stickiness when fusion positivity is present.
• Ongoing label expansions: New cohorts can extend the addressable market without replacing the original population.
• Safety and monitoring requirements: These affect adherence and payer willingness to approve.

---

How do reimbursement and payer dynamics shape VITRAKVI revenue?

Answer (snapshot): VITRAKVI’s revenue is payer-controlled via coverage criteria tied to NTRK fusion confirmation, line-of-therapy rules, and prior authorization documentation. Even with broad label coverage, payer friction can slow adoption.

Typical reimbursement levers

• Prior authorization: Requires evidence of NTRK fusion positivity (test type, report, and methodology).
• Step therapy: Some payers impose prior chemotherapy or other targeted therapy steps based on label language.
• Center of excellence routing: Some health systems route biomarker-driven oncology to specific oncology networks.

What changes revenue in practice

• Automation of biomarker documentation: reduces administrative friction and increases conversion rate.
• Contracting with specialty pharmacy: improves adherence, reduces delays, and supports longer treatment duration.

---

Which indications and patient segments contribute most to VITRAKVI revenue?

Answer (snapshot): Revenue concentration tends to be highest in settings with the most frequent NTRK fusion testing and the strongest guideline-driven trial uptake. Pediatric and rare adult solid tumors are high-impact segments in TRK inhibitor franchises because they represent the clearest “fit” for biomarker-driven targeted therapy.

Revenue segmentation model

• Pediatric solid tumors with NTRK fusions: high share relative to population size; longer duration increases lifetime revenue.
• Adult solid tumors with NTRK fusions: adoption depends on community oncology testing and payer documentation efficiency.
• Line-of-therapy buckets: first and second line typically offer better persistence and share stability than refractory later lines.

---

How do VITRAKVI manufacturing and supply-chain constraints affect financial performance?

Answer (snapshot): For oral oncology therapies, revenue risk is dominated by sustained supply availability and quality system performance rather than capacity bottlenecks, but any manufacturing disruption can create short-term reimbursement and adherence losses.

What to monitor for revenue continuity

• Lot release delays: impact fulfillment and treatment starts.
• API or key intermediate sourcing risk: affects continuity of supply.
• Regulatory inspections: can lead to temporary production holds.

---

Key financial trajectory drivers summarized for investment and licensing decisions

• Adoption curve: Testing access and conversion of positive results into prescriptions drive patient starts.
• Persistence: Durable responders create a compounding revenue stream.
• Payer policy: Prior authorization and step-therapy requirements directly impact net sales vs gross demand.
• Competitive class dynamics: Switching within TRK inhibitors occurs when toxicity profiles or response characteristics favor alternatives.
• Exclusivity and patent calendar: Determines when the market can price in generic entry risk.

---

Key Takeaways

• VITRAKVI’s market performance is constrained primarily by NTRK fusion testing access and payer authorization friction, not by label limitations.
• The revenue trajectory tends to be sustained by tumor-agnostic adoption and durable treatment in responders, with persistence acting as a major determinant of lifetime value.
• Generic entry risk hinges on the patent estate and Orange Book-listed barriers, with Paragraph IV and settlement outcomes driving the most material discontinuities in pricing and volume.
• Competitive pressure within TRK inhibitors is less about efficacy head-to-head in all-comers and more about real-world tolerability, treatment switching, and contracting outcomes by segment.
• Financial forecasting should model patient starts based on testing penetration plus persistence based on adverse event management, then apply a discrete risk overlay from patent expiry and litigation outcomes.

---

FAQs

1. What launches pose the largest sales risk for VITRAKVI in TRK fusion oncology?
2. How does NTRK fusion testing uptake correlate with quarterly VITRAKVI net sales?
3. Which payer restrictions most commonly delay VITRAKVI treatment starts?
4. How should investors model revenue under different Paragraph IV litigation outcomes for larotrectinib patents?
5. What real-world factors most influence VITRAKVI persistence and discontinuation rates?

---

References

No sources were provided in the prompt, and no citations can be generated without verifiable publication details (e.g., Orange Book listings, FDA label timeline, or company financial reports).

DrugChatter Q&A for VITRAKVI

Vitrakvi bayer loss of patent?
Vitrakvi bayer perte de brevet loe?